Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences, Inc. (OTC: EVFM) regularly issues news and updates focused on women’s sexual and reproductive health, its FDA-approved products, and its corporate strategy. Company press releases highlight developments around PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
News items cover a range of topics, including quarterly and annual financial results, cost-of-goods initiatives, and progress on international expansion. For example, Evofem has announced licensing arrangements with Pharma 1 Drug Store in the Middle East and North Africa, regulatory submissions for PHEXXI and SOLOSEC in the United Arab Emirates, and steps toward commercialization in Gulf Cooperation Council states. These updates provide context on how the company is seeking to diversify and expand its revenue stream beyond the United States.
Evofem’s releases also describe marketing and educational campaigns such as the "Say Vagina" initiative, which the company presents as an effort to normalize clinical language and address stigma around vaginal health. Other news has detailed the impact of social media campaigns on traffic to the PHEXXI website, engagement from healthcare providers, and broader brand awareness.
In addition, investors can find news about corporate actions and governance, including information on a previously proposed merger with Aditxt, Inc. and its subsequent termination, reverse stock split authorization, and capital raises through notes and warrants. This news page aggregates such announcements so readers can follow product, regulatory, commercial, and corporate developments related to Evofem Biosciences and its EVFM stock symbol over time.
Evofem Biosciences (NASDAQ: EVFM) announced the submission of its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS on November 10, 2021. This submission marks a critical step in expanding access to Femidence™ for women in Mexico and aligns with Evofem's 2020 Global Health Agreement with Adjuvant Capital. If approved, Femidence™ could be available in early 2023. The company aims to provide effective reproductive health solutions for low and middle-income countries.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 1:20 p.m. ET. The event will feature a fireside chat format in Track 2. Interested parties can access a live and archived webcast on the company’s website. Evofem is focused on women's reproductive health, with its FDA-approved product, Phexxi®, being a hormone-free contraceptive. One-on-one meetings can be arranged through Stifel for attendees.
Evofem Biosciences (NASDAQ: EVFM) will host a webcast and conference call on November 15, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial results and business highlights. Investors can access the live and archived webcast through a link on their investor room page. Participation by phone is also available, and a replay will be provided for 24 hours after the call. Evofem focuses on women's sexual and reproductive health, with its primary product being Phexxi®, a hormone-free contraceptive gel.
Evofem Biosciences (NASDAQ: EVFM) reported promising results from its "House Rules" DTC campaign featuring Annie Murphy, aimed at promoting Phexxi, a hormone-free contraceptive. The campaign has achieved 2 billion media impressions and led to a 263% increase in website traffic. Key metrics show a 71% rise in sales and a 56% increase in new users for Phexxi in September compared to August 2021. Over 8,900 units of Phexxi were dispensed, with 7,839 prescriptions issued. The campaign targets women seeking alternatives to hormonal contraceptives.
Evofem Biosciences has announced a registered direct offering of 10,000 shares of Series B Convertible Stock at $1,000 per share, totaling approximately $10 million in gross proceeds. The sale will close in two tranches, with the initial closing occurring shortly after the announcement. Funds will support Phexxi® commercialization, the Phase 3 clinical trial 'EVOGUARD' for preventing chlamydia and gonorrhea, and general corporate purposes. The offering is part of Evofem's strategy to enhance shareholder value and maintain cash flow into Q1 2022.
Evofem Biosciences, Inc. (NASDAQ: EVFM) praised House leaders for advocating coverage of all FDA-approved contraceptives under the Affordable Care Act (ACA). CEO Saundra Pelletier recognized the importance of the House's letter, which requests senior Biden Administration officials to ensure compliance with ACA requirements. The company's product, Phexxi, is a hormone-free contraceptive gel approved by the FDA in May 2020. Evofem focuses on women's reproductive health solutions, including contraception and protection against STIs.
Evofem Biosciences (NASDAQ: EVFM) announced its CEO, Saundra Pelletier, will present at the LD Micro Main Event in Los Angeles from October 12-14, 2021. The presentation is scheduled for October 12 at 12:30 p.m. PT. The company recently launched a new campaign, "House Rules," on September 9, 2021, to promote its hormone-free contraceptive, Phexxi. The campaign has successfully increased media coverage, site traffic, and telehealth visits, enhancing Phexxi prescription growth. Interested parties can register for the virtual presentation via the company website.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced the publication of a manuscript in Advances in Therapy, discussing variability in contraceptive clinical trial designs and their impact on efficacy outcomes. The study highlights challenges in comparing efficacy across non-hormonal and hormonal contraception due to variations in trial protocols. Key findings show that the exclusion of certain menstrual cycles can misrepresent the effectiveness of contraceptives. The paper aims to raise awareness among healthcare providers regarding these nuances, thereby improving contraceptive counseling.
Evofem Biosciences (NASDAQ: EVFM) announced the presentation of seven clinical trial data sets on its products, Phexxi and EVO100, at four medical society meetings in October 2021. Leading the presentations is Dr. Brandi Howard, who highlighted significant interest from healthcare providers. The posters will cover topics including genitourinary symptoms and the effectiveness of the vaginal pH modulator in preventing STIs. Notably, the AMPREVENCE study showcased statistically significant reductions in the risk of chlamydia and gonorrhea infections. The abstracts will be published in relevant medical journals.
Summary not available.